Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report.

Ebeling PR, Akesson K, Bauer DC, Buchbinder R, Eastell R, Fink HA, Giangregorio L, Guanabens N, Kado D, Kallmes D, Katzman W, Rodriguez A, Wermers R, Wilson HA, Bouxsein ML.

J Bone Miner Res. 2019 Jan;34(1):3-21. doi: 10.1002/jbmr.3653.

PMID:
30677181
2.

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.

Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM; FNIH Bone Quality Project.

J Bone Miner Res. 2019 Jan 23. doi: 10.1002/jbmr.3641. [Epub ahead of print]

PMID:
30674078
3.

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.

Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM.

Osteoporos Int. 2019 Mar;30(3):667-673. doi: 10.1007/s00198-018-04819-1. Epub 2019 Jan 11.

4.

Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.

Naylor KE, McCloskey EV, Jacques RM, Peel NFA, Paggiosi MA, Gossiel F, Walsh JS, Eastell R.

Osteoporos Int. 2019 Jan 6. doi: 10.1007/s00198-018-04823-5. [Epub ahead of print]

PMID:
30613868
5.

Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials.

Kim TY, Bauer DC, McNabb BL, Schafer AL, Cosman F, Black DM, Eastell R.

J Bone Miner Res. 2018 Dec 7. doi: 10.1002/jbmr.3654. [Epub ahead of print]

PMID:
30536713
6.

Discordant pattern of peripheral fractures in diabetes: a meta-analysis on the risk of wrist and ankle fractures.

Vilaca T, Walsh J, Eastell R.

Osteoporos Int. 2019 Jan;30(1):135-143. doi: 10.1007/s00198-018-4717-0. Epub 2018 Oct 10.

PMID:
30306223
7.

Developing a toolkit for the assessment and monitoring of musculoskeletal ageing.

Kemp GJ, Birrell F, Clegg PD, Cuthbertson DJ, De Vito G, van Dieën JH, Del Din S, Eastell R, Garnero P, Goljanek-Whysall K, Hackl M, Hodgson R, Jackson MJ, Lord S, Mazzà C, McArdle A, McCloskey EV, Narici M, Peffers MJ, Schiaffino S, Mathers JC.

Age Ageing. 2018 Sep 1;47(suppl_4):iv1-iv19. doi: 10.1093/ageing/afy143.

8.

Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Szulc P, Naylor K, Pickering ME, Hoyle N, Eastell R, Leary E.

Ann Biol Clin (Paris). 2018 Aug 1;76(4):373-391. doi: 10.1684/abc.2018.1363. Review.

PMID:
30078776
9.

Effect of vitamin D supplementation on free and total vitamin D: A comparison of Asians and Caucasians.

Gopal-Kothandapani JS, Evans LF, Walsh JS, Gossiel F, Rigby AS, Eastell R, Bishop NJ.

Clin Endocrinol (Oxf). 2019 Jan;90(1):222-231. doi: 10.1111/cen.13825. Epub 2018 Sep 9.

PMID:
30067874
10.

Diagnosis and management of bone fragility in diabetes: an emerging challenge.

Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, El-Hajj Fuleihan G, Josse R, Kendler DL, Kraenzlin M, Suzuki A, Pierroz DD, Schwartz AV, Leslie WD; Bone and Diabetes Working Group of IOF.

Osteoporos Int. 2018 Dec;29(12):2585-2596. doi: 10.1007/s00198-018-4650-2. Epub 2018 Jul 31. Review.

11.

Authors' Reply.

Salam S, Khwaja A, Eastell R.

J Am Soc Nephrol. 2018 Sep;29(9):2444. doi: 10.1681/ASN.2018060647. Epub 2018 Jul 30. No abstract available.

PMID:
30061453
12.

Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations.

Schwartz JB, Gallagher JC, Jorde R, Berg V, Walsh J, Eastell R, Evans AL, Bowles S, Naylor KE, Jones KS, Schoenmakers I, Holick M, Orwoll E, Nielson C, Kaufmann M, Jones G, Bouillon R, Lai J, Verotta D, Bikle D.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3278-3288. doi: 10.1210/jc.2018-00295.

PMID:
29955795
13.

Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.

Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R.

J Am Soc Nephrol. 2018 May;29(5):1557-1565. doi: 10.1681/ASN.2017050584. Epub 2018 Mar 19.

14.

Bone turnover markers after the menopause: T-score approach.

Gossiel F, Altaher H, Reid DM, Roux C, Felsenberg D, Glüer CC, Eastell R.

Bone. 2018 Jun;111:44-48. doi: 10.1016/j.bone.2018.03.016. Epub 2018 Mar 15.

PMID:
29551751
15.

Comparison of femoral strength and fracture risk index derived from DXA-based finite element analysis for stratifying hip fracture risk: A cross-sectional study.

Yang S, Luo Y, Yang L, Dall'Ara E, Eastell R, Goertzen AL, McCloskey EV, Leslie WD, Lix LM.

Bone. 2018 May;110:386-391. doi: 10.1016/j.bone.2018.03.005. Epub 2018 Mar 8.

PMID:
29526781
16.

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.

Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.

Osteoporos Int. 2018 Jun;29(6):1407-1417. doi: 10.1007/s00198-018-4460-6. Epub 2018 Mar 10.

17.

Bone: Microarchitecture of bone predicts fractures in older women.

Eastell R, Walsh JS.

Nat Rev Endocrinol. 2018 May;14(5):255-256. doi: 10.1038/nrendo.2018.27. Epub 2018 Mar 9. No abstract available.

18.

Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.

Paggiosi MA, Yang L, Blackwell D, Walsh JS, McCloskey E, Peel N, Eastell R.

Osteoporos Int. 2018 Jun;29(6):1367-1378. doi: 10.1007/s00198-018-4445-5. Epub 2018 Mar 8.

19.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR.

Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13.

20.

Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.

Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1302-1309. doi: 10.1210/jc.2017-00283.

21.

A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases.

Cummings SR, Eastell R.

J Bone Miner Res. 2018 Jan;33(1):5-12. doi: 10.1002/jbmr.3353. Epub 2018 Jan 12. No abstract available.

22.

Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression.

Bauer DC, Black DM, Bouxsein ML, Lui LY, Cauley JA, de Papp AE, Grauer A, Khosla S, McCulloch CE, Eastell R; Foundation for the National Institutes of Health (FNIH) Bone Quality Project.

J Bone Miner Res. 2018 Apr;33(4):634-642. doi: 10.1002/jbmr.3355. Epub 2018 Jan 10.

23.

Anabolic treatment for osteoporosis: teriparatide.

Eastell R, Walsh JS.

Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):173-178. doi: 10.11138/ccmbm/2017.14.1.173. Epub 2017 Oct 25. Review.

24.

Association of incident hip fracture with the estimated femoral strength by finite element analysis of DXA scans in the Osteoporotic Fractures in Men (MrOS) study.

Yang L, Parimi N, Orwoll ES, Black DM, Schousboe JT, Eastell R; Osteoporotic Fractures in Men (MrOS) Study Research Group.

Osteoporos Int. 2018 Mar;29(3):643-651. doi: 10.1007/s00198-017-4319-2. Epub 2017 Nov 22.

25.

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.

Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP.

J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22.

26.

DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?

Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA.

Eur J Endocrinol. 2018 Jan;178(1):R19-R31. doi: 10.1530/EJE-17-0585. Epub 2017 Oct 18. Review.

27.

Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts.

Segna D, Bauer DC, Feller M, Schneider C, Fink HA, Aubert CE, Collet TH, da Costa BR, Fischer K, Peeters RP, Cappola AR, Blum MR, van Dorland HA, Robbins J, Naylor K, Eastell R, Uitterlinden AG, Rivadeneira Ramirez F, Gogakos A, Gussekloo J, Williams GR, Schwartz A, Cauley JA, Aujesky DA, Bischoff-Ferrari HA, Rodondi N; Thyroid Studies Collaboration.

J Intern Med. 2018 Jan;283(1):56-72. doi: 10.1111/joim.12688. Epub 2017 Oct 16.

28.

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC.

Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5. Review.

PMID:
28789921
29.

Bone Turnover Markers: Use in Fracture Prediction.

Vilaca T, Gossiel F, Eastell R.

J Clin Densitom. 2017 Jul - Sep;20(3):346-352. doi: 10.1016/j.jocd.2017.06.020. Epub 2017 Jul 14. Review.

PMID:
28716498
30.

Use of bone turnover markers in postmenopausal osteoporosis.

Eastell R, Szulc P.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):908-923. doi: 10.1016/S2213-8587(17)30184-5. Epub 2017 Jul 7. Review.

PMID:
28689768
31.

Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.

Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B.

Osteoporos Int. 2017 Oct;28(10):2921-2928. doi: 10.1007/s00198-017-4132-y. Epub 2017 Jun 29.

PMID:
28664276
32.

Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET; National Bone Health Alliance Bone Turnover Marker Project.

Osteoporos Int. 2017 Sep;28(9):2541-2556. doi: 10.1007/s00198-017-4082-4. Epub 2017 Jun 19. Review.

PMID:
28631236
33.

Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.

Tanaka M, Hashimoto Y, Hasegawa C, Deacon S, Eastell R.

BMC Musculoskelet Disord. 2017 Jun 19;18(1):267. doi: 10.1186/s12891-017-1625-y.

34.

Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research.

Rodriguez AJ, Fink HA, Mirigian L, Guañabens N, Eastell R, Akesson K, Bauer DC, Ebeling PR.

J Bone Miner Res. 2017 Sep;32(9):1935-1944. doi: 10.1002/jbmr.3170. Epub 2017 Jun 26. Review.

35.

Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts.

Aubert CE, Floriani C, Bauer DC, da Costa BR, Segna D, Blum MR, Collet TH, Fink HA, Cappola AR, Syrogiannouli L, Peeters RP, Åsvold BO, den Elzen WPJ, Luben RN, Bremner AP, Gogakos A, Eastell R, Kearney PM, Hoff M, Le Blanc E, Ceresini G, Rivadeneira F, Uitterlinden AG, Khaw KT, Langhammer A, Stott DJ, Westendorp RGJ, Ferrucci L, Williams GR, Gussekloo J, Walsh JP, Aujesky D, Rodondi N; Thyroid Studies Collaboration.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2719-2728. doi: 10.1210/jc.2017-00294.

36.

Development and validation of a subject-specific finite element model of the functional spinal unit to predict vertebral strength.

Lee CH, Landham PR, Eastell R, Adams MA, Dolan P, Yang L.

Proc Inst Mech Eng H. 2017 Sep;231(9):821-830. doi: 10.1177/0954411917708806. Epub 2017 May 6.

PMID:
28478734
37.

Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over.

Armbrecht G, Felsenberg D, Ganswindt M, Lunt M, Kaptoge SK, Abendroth K, Aroso Dias A, Bhalla AK, Cannata Andia J, Dequeker J, Eastell R, Hoszowski K, Lyritis G, Masaryk P, van Meurs J, Miazgowski T, Nuti R, Poór G, Redlund-Johnell I, Reid DM, Schatz H, Todd CJ, Woolf AD, Rivadeneira F, Javaid MK, Cooper C, Silman AJ, O'Neill TW, Reeve J; European Vertebral Osteoporosis Study and European Prospective Osteoporosis Study Groups.

Rheumatology (Oxford). 2017 Jul 1;56(7):1189-1199. doi: 10.1093/rheumatology/kex040.

38.

Effect of age and gender on serum periostin: Relationship to cortical measures, bone turnover and hormones.

Walsh JS, Gossiel F, Scott JR, Paggiosi MA, Eastell R.

Bone. 2017 Jun;99:8-13. doi: 10.1016/j.bone.2017.03.041. Epub 2017 Mar 16.

39.

Higher bone resorption excretion in South Asian women vs. White Caucasians and increased bone loss with higher seasonal cycling of vitamin D: Results from the D-FINES cohort study.

Darling AL, Hart KH, Gossiel F, Robertson F, Hunt J, Hill TR, Johnsen S, Berry JL, Eastell R, Vieth R, Lanham-New SA.

Bone. 2017 May;98:47-53. doi: 10.1016/j.bone.2017.03.002. Epub 2017 Mar 7.

40.

Recommendations for the screening of adherence to oral bisphosphonates: reply to comments by Zhou and Sheng.

Eastell R, Diez-Perez A.

Osteoporos Int. 2017 Jul;28(7):2257-2258. doi: 10.1007/s00198-017-3991-6. Epub 2017 Mar 10. No abstract available.

PMID:
28283689
41.

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.

Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, Dennison E, Eriksen EF, Gold DT, Guañabens N, Hadji P, Hiligsmann M, Horne R, Josse R, Kanis JA, Obermayer-Pietsch B, Prieto-Alhambra D, Reginster JY, Rizzoli R, Silverman S, Zillikens MC, Eastell R; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society.

Osteoporos Int. 2017 Mar;28(3):767-774. doi: 10.1007/s00198-017-3906-6. Epub 2017 Jan 16.

42.

Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.

Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw.

J Clin Densitom. 2017 Jan - Mar;20(1):8-24. doi: 10.1016/j.jocd.2016.09.005. Epub 2016 Dec 9. Review.

PMID:
27956123
43.

Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia.

Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, Cooper C, Eastell R, Wordsworth P, Javaid MK, Pinedo-Villanueva R.

Orphanet J Rare Dis. 2016 Nov 28;11(1):160.

44.

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.

Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan De Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S.

J Bone Miner Res. 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039. Epub 2016 Dec 27.

45.

The RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseases.

Javaid MK, Forestier-Zhang L, Watts L, Turner A, Ponte C, Teare H, Gray D, Gray N, Popert R, Hogg J, Barrett J, Pinedo-Villanueva R, Cooper C, Eastell R, Bishop N, Luqmani R, Wordsworth P, Kaye J.

Orphanet J Rare Dis. 2016 Nov 8;11(1):150.

46.

Risk and Prevention of Fracture in Patients With Major Medical Illnesses: A Mini-Review.

Cummings SR, Eastell R.

J Bone Miner Res. 2016 Dec;31(12):2069-2072. doi: 10.1002/jbmr.3030. Review.

47.

Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy.

Moon RJ, Harvey NC, Cooper C, D'Angelo S, Crozier SR, Inskip HM, Schoenmakers I, Prentice A, Arden NK, Bishop NJ, Carr A, Dennison EM, Eastell R, Fraser R, Gandhi SV, Godfrey KM, Kennedy S, Mughal MZ, Papageorghiou AT, Reid DM, Robinson SM, Javaid MK.

J Clin Endocrinol Metab. 2016 Dec;101(12):5012-5020. Epub 2016 Oct 27.

48.

Postmenopausal osteoporosis.

Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR.

Nat Rev Dis Primers. 2016 Sep 29;2:16069. doi: 10.1038/nrdp.2016.69. Review.

PMID:
27681935
49.

Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP.

Osteoporos Int. 2017 Jan;28(1):1-19. doi: 10.1007/s00198-016-3716-2. Epub 2016 Sep 9. Review.

50.

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study.

Gossiel F, Hoyle C, McCloskey EV, Naylor KE, Walsh J, Peel N, Eastell R.

Bone. 2016 Nov;92:94-99. doi: 10.1016/j.bone.2016.08.010. Epub 2016 Aug 12.

Supplemental Content

Loading ...
Support Center